External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home 2021 GI Cancers Symposium
Roche and Genentech at

2021 GI Cancers Symposium

January 15 - January 17
Virtual
conferences.asco.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
03:30 PM
Duration 5mins Virtual
IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase 3 study of ▼atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
RS Finn, S Qin, M Ikeda, P Galle, M Ducreux, TY Kim, HY Lim, M Kudo, V Breder, P Merle, A Kaseb, D Li, W Verret, H Shao, J Liu, L Li, AX Zhu, AL Cheng
Oncology | Gastrointestinal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.